Logo

Rubicon to Help Genome Institute of Singapore in Hep B Vaccine Research

Jul 21, 2005

NEW YORK, July 21 (GenomeWeb News) - Rubicon Genomics will extract small amounts of DNA from archived serum samples for the Genome Institute of Singapore, the Ann Arbor, Mich.-based company said today.

 

Under the agreement, Rubicon will isolate and amplify genomic DNA from 5,000 serum samples from a hepatitis B vaccine trial using its technology, which enables researchers to purify DNA from as few as 10 cells.

 

GIS plans to use the DNA in an international study with researchers in Indonesiaand the Netherlandsto discover genes important for hepatitis B prevention and treatment.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.